کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3477735 1233359 2014 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Interleukin-21 Receptor Might be a Novel Therapeutic Target for the Treatment of Rheumatoid Arthritis
ترجمه فارسی عنوان
گیرنده اینترلوکین 21 ممکن است یک هدف درمانی روان برای درمان آرتریت روماتوئید باشد
کلمات کلیدی
بیماری خودایمنی، اینترلوکین 21، گیرنده اینترلوکین 21، آرتریت روماتوئید
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی پزشکی و دندانپزشکی (عمومی)
چکیده انگلیسی

BackgroundRheumatoid arthritis (RA) is a chronic autoimmune disease characterized by the synovial inflammation of the joints. Various cells and cytokines have been identified that may contribute to RA pathology. Interleukin (IL)-21 is a proinflammatory cytokine mediating pleiotropic functions through the IL-21 receptor (IL-21R). Blockade of IL-21R may represent a hopeful therapeutic approach in RA. The aim of this study was to determine the percentage of IL-21R expressing CD4+ cells and IL-21 mRNA expression in peripheral blood of RA patients.MethodsSurface expression of IL-21R on CD4+ cells in peripheral blood of RA patients (n = 32 compared to healthy control participants (n = 20) was evaluated by flow cytometry. Simultaneously, mononuclear cells were taken apart from the peripheral blood of individuals on a density gradient. The expression of IL-21 mRNA was assessed by real-time polymerase chain reaction.ResultsIL-21R-expressing CD4+ cells from RA patients showed a significantly higher percentage of IL-21R compared with healthy controls (p < 0.05). Moreover, real-time polymerase chain reaction showed that there was no significant difference between patients and healthy controls.ConclusionOur results indicate higher expression of IL-21R in RA patients and suggest that targeting of the IL-21R may be a novel therapeutic idea for the treatment of RA.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Experimental & Clinical Medicine - Volume 6, Issue 2, April 2014, Pages 57–61
نویسندگان
, , , , , , ,